Pathogenic PF4/Polyanion ELISA-Negative Antibodies in HIT

Area of Science:

• Immunology
• Hematology
• Clinical Diagnostics

Background:

• Platelet factor 4-polyanion enzyme-linked immunosorbent assays (ELISAs) are standard for diagnosing heparin-induced thrombocytopenia (HIT).
• Current guidelines rely on ELISA-negative results to exclude HIT, leading to cessation of alternative anticoagulants and potential heparin reintroduction.
• This practice may pose risks for patients with ELISA-negative HIT.

Purpose of the Study:

• To investigate the presence and pathogenic potential of HIT antibodies in patients testing negative via standard ELISA.
• To evaluate the utility of functional assays in identifying ELISA-negative HIT cases.
• To highlight the clinical implications of recognizing ELISA-negative HIT.

Main Methods:

• Utilized antigen-based and PF4-dependent functional testing to analyze sera from HIT-suspected patients.
• Examined PF4/polyvinylsulfonate (PF4/PVS) ELISA-negative samples for platelet-activating antibodies.
• Assessed antibody activity using platelet FcγRIIa receptor blockade and heparin inhibition assays.

Main Results:

• Identified three patients with clinical HIT presentations who were ELISA-negative but showed PF4-dependent platelet activation.
• Functional testing identified three additional ELISA-negative patients with HIT-like clinical histories and pathogenic antibodies.
• Five of six ELISA-negative HIT patients experienced platelet count drops upon heparin re-exposure; one developed a new thrombus.

Conclusions:

• ELISA-negative HIT is a clinically significant entity that can be identified through functional assays.
• Failure to recognize ELISA-negative HIT can lead to inappropriate cessation of alternative anticoagulation and dangerous heparin re-exposure.
• Accurate diagnosis of all HIT cases, including ELISA-negative ones, is critical for patient safety and effective treatment.